BPC-157  Research Summary
Pentadecapeptide derived from human gastric juice, studied for cytoprotective an
BPC-157
An evidence summary of published preclinical research on BPC-157. This page is educational and summarizes findings reported in third-party scientific literature. No claims are made regarding safety or efficacy in humans.
Molecular Data
Compound Overview
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a partial sequence of a protein found in human gastric juice. Since its discovery in the early 1990s, BPC-157 has become one of the most extensively studied peptides in preclinical tissue repair and regeneration research. Unlike many bioactive peptides, BPC-157 demonstrates remarkable stability in human gastric juice, which has drawn significant scientific interest.
Reported Mechanism (Preclinical)
Research suggests BPC-157 exerts its effects through multiple pathways: upregulation of growth factor expression (EGF, VEGF, FGF), modulation of the nitric oxide (NO) system, interaction with the dopaminergic and serotonergic systems, and promotion of angiogenesis (formation of new blood vessels). Studies indicate it may accelerate the formation of granulation tissue, enhance collagen deposition, and promote organized tissue remodeling at injury sites.
Mechanisms described above are reported in preclinical (animal and in vitro) literature and have not been established for human use.
Key Research Highlights
- Accelerated tendon-to-bone healing in rat rotator cuff injury models (Chang et al., 2011)
- Enhanced muscle healing after crush injuries with improved functional recovery (Pevec et al., 2010)
- Demonstrated cytoprotective effects against NSAID-induced gastrointestinal damage (Sikiric et al., 2006)
- Promoted angiogenesis and accelerated wound healing in cutaneous wound models
- Showed neuroprotective properties in models of peripheral nerve damage
Published References
-
BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Med Hypotheses, 2011 -
Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy
Eur J Pharmacol, 2006 -
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease
Curr Pharm Des, 2003
Available for Research
Lab-tested, third-party COA published, U.S. ships same day.
View Product · BPC-157 View COA Library